Bristol-Myers Squibb Zerit and Videx
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Black-box warnings and the "Warnings" and "Precautions" sections of labeling for Zerit (stavudine), Videx (didanosine) and Videx EC will be strengthened following reports of fatal lactic acidosis in the infants of pregnant women taking a combination of Videx and Zerit. "Fatal lactic acidosis has been reported in pregnant women who received the combination of didanosine and stavudine with other retroviral agents," the revised black-box warning says. "The combination of didanosine and stavudine should be used with caution during pregnancy and is recommended only if the potential benefit outweighs the risk
You may also be interested in...
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.